

Supplementary Table 1. Disease flares and chronic damage in patients with AAV according to serological and clinicopathological classifications¹

	PR3-AAV (n = 131)	MPO-AAV (n = 66)	P	GPA (n = 148)	MPA (n = 48)	P-value
Number of subjects with at least 1 severe flare by 18 months (%)	33 (25.2)	8 (12.1)	0.03	36 (24.5)	5 (10.4)	0.04
Number of subjects with ≥ 1 limited flare by 18 months (%)	41 (31.3)	10 (15.2)	0.02	45 (30.6)	6 (12.5)	0.01
Time to first flare (days), median (IQR)	153 (92; 200)	161 (38; 280)	0.82	148 (92; 199)	257 (136; 281)	0.30
VDI by 18 months	2.2 (2.0)	2.5 (2.3)	0.02	2.2 (2.1)	2.6 (2.2)	<0.01

¹One patient had an indeterminate type of AAV. AAV = ANCA-associated vasculitis; IQR = interquartile range; VDI = vasculitis damage index; SD = standard deviation